Small RNAs/Functional Genomics
Support and Educational Content

Tips for successful lncRNA knockdown: Design, delivery, and analysis of antisense and RNAi reagents


Approaches for studying lncRNA function

Discussions on cellular RNA should not begin and end with the all-familiar protein-coding mRNA. In fact, it is becoming clear that non-coding RNA plays a very important role in the cell—especially for complex organisms. A meta-analysis of the amount of protein-coding RNA versus non-coding RNA, relative to the size and complexity of an organism, shows that protein-coding RNA plateaus as complexity increases, while non-coding RNA continues to increase [1]. In fact, there are believed to be over 60,000 non-coding RNAs in humans, compared to only 20,000 protein-coding genes. This intriguing trend has provoked many researchers to study long non-coding RNAs (lncRNAs), a type of non-coding RNA involved in spatial and temporal regulation of protein-coding genes.

Researchers can study lncRNA function by suppressing expression and observing resulting phenotypes—a technique known as lncRNA knockdown. The 2 main approaches to experimentally achieve this are by using antisense oligonucleotides (ASOs) and RNA interference (RNAi). (See the article, A new renaissance for antisense in the era of lncRNA, for further discussion.) Knockdown with these reagents is not always easy, however, as there are many factors that can lead to incorrect or uninterpretable results.

IDT scientist Kim Lennox specializes in developing tools for gene and RNA regulation. She has several publications in these fields [2–4], and she has also presented a webinar entitled, Knockdown of lncRNAs: exploring RNAi and antisense oligo methods. Here, Kim provides some tips for successful lncRNA knockdown.


Reagent design and target selection

Directing well-designed reagents to the most effective target region is crucial for achieving successful knockdown. Here are the most important considerations.

Screen for effective ASO targets sites. Some regions of the lncRNA sequence are better ASO target sites than others. Identifying the most potent target sites for ASOs can be a challenge because there are currently no predictive algorithms for determining target accessibility. Using a software package such as UNAFold (IDT), however, can help predict lncRNA secondary structure. The ASOs designed by IDT are typically 20mer oligonucleotides with 40–60% GC content and are designed to have minimal secondary structure and self-dimerization potential. (To check secondary structure over a longer region of the target sequence, contact Rensselaer Polytechnic Institute, for a larger, licensed version of the UNAFold software.)

It is also important to verify that the ASO does not inadvertently target another closely related RNA sequence—target sites with >80% sequence identity with other RNAs should be excluded.

Improve the success of identifying potent ASO sites by screening at least 5 sites. To minimize cost, use phophorothioate (PS)-linked, desalted DNA oligos for the screening assays (Figure 1). After an accessible site is found, 2′-O-methyl RNA can be added to the PS-modified DNA ASO to form a chimeric 2′OMe-PS gapmer (Figure 2). The addition of 2′-O-methyl RNA reduces ASO toxicity and increases Tm—which increases ASO potency. IDT is currently developing algorithms for improved site prediction to drive an online tool for designing ASOs.

Figure 1. A phosphorothioate bond added to ASOs provides resistance from serum and intracellular nucleases.

Figure 2. Recommended ASO design for lncRNA knockdown.

Consider lncRNA secondary structure. The structure of the target can have a large impact on the efficiency of a knockdown reagent. When using RNAi, helicase activity in RISC is thought to unwind the target sequence, which greatly increases accessibility of the target. ASOs, on the other hand, rely exclusively on thermodynamics for target site binding, and it is difficult to computationally predict their ability to invade a sequence which is highly structured. Having said that, UNAFold software from IDT can be used to search for accessible target regions prior to ASO design, and this can improve efficiency.

Choose an effective lncRNA target length. Cleaved mRNAs that are translated into truncated, non-functional proteins will show accurate phenotypic changes, even if the RNA is not entirely degraded by ribonucleases. However, lncRNAs do not encode proteins, and may retain their function in the cell after cleavage, if active fragments remain. Therefore, lncRNA length can impact effective knockdown. The incidence of remaining active lncRNA fragments may increase with lncRNA protein binding, binding to other nucleic acids, or if the lncRNA has a complex structure, as these interactions can hinder the ability of ribonucleases to degrade the RNA. Unlike mRNAs, retaining a functional lncRNA domain can lead to erroneous phenotypes when examining knockdown.

We have worked with lncRNAs up to 10 kb in length, and have not observed retained functional lncRNA fragments. That said, the possible retention of functional fragments is an important consideration for all targeted lncRNA regions. This problem might not be entirely length dependent since protein binding, secondary structure, and even cell type can all be contributory factors. To determine whether there is complete degradation of the lncRNA, measure lncRNA knockdown by using at least 2 qPCR assays targeting opposite ends of the lncRNA sequence. If retained fragments are detected, it might be necessary to use multiple knockdown reagents distributed throughout the lncRNA sequence.

Work around lncRNA splice regions. Most lncRNAs are spliced, which can further complicate target region identification. It is important to target the correct isoform(s), and the use of multiple isoform specific qPCR assays can be helpful in doing this. For example, if targeting one isoform, design a qPCR assay that only amplifies that isoform. Further confirmation can be provided by designing a negative control qPCR assay that amplifies an isoform not intended for knockdown, to show that knockdown of that isoform did not occur. To knockdown multiple isoforms, design a qPCR assay that amplifies all (and only) the isoforms you are interested in. Though there are discrepancies in lncRNA annotation, advances in transcriptomics and high-throughput sequencing are facilitating the fast accumulation of lncRNA data sets, which are being collected and organized into large databases such as Ensembl, lncRNome, and LNCipedia [5].


Cell delivery

Effective delivery of knockdown reagents into the cell is extremely important, but is often challenging. Below are tips to help ensure successful reagent delivery.

Choose reagents appropriate for your cell line. For cell culture, transfection efficiency is cell line specific. ASO delivery using Lipofectamine® 2000 Reagent (ThermoFisher Scientific) has been shown to work exceptionally well in several common laboratory cell lines [2, 6]. However, ASO reagents can be toxic to cells, especially at doses >20 nM. If toxicity is found to be an issue, Lipofectamine® RNAiMAX Reagent (ThermoFisher Scientific) can be used as an alternative. Although RNAiMAX is an RNAi reagent, it is less toxic and has been seen to perform equally well with ASOs and siRNAs.

IDT scientists can provide reagent recommendations for a variety of cell lines. In some cases, particularly when using primary cells, electroporation can provide the best results. It is always important to include a positive control ASO to verify transfection efficiency, especially when working with new cell lines or new chemical classes of nucleic acids. For example, the optimum transfection method varies not only between cell types but also for plasmids, single-stranded ASOs, and double-stranded siRNAs.

Include a delivery reagent for in vivo injection. When performing lncRNA knockdown in vivo, we do not recommend using naked IV injection. It is more effective to use a delivery tool, such as a lipid nanoparticle or polymer system.


Knockdown analysis

Following successful design and delivery of reagents, it is essential to measure lncRNA knockdown accurately. Consider these tips for analyzing knockdown data.

Design efficient qPCR assays. Rather than designing an RT-qPCR reaction for every binding site on every target, we recommend designing 2 qPCR assays, one each at the 5′ and 3′ ends of the target sequence. If, after amplification, you find the same change in expression level with the 5′ and 3′ end assays, you can assume that all fragments in between the ends have undergone the same change in expression (Figure 3). This experimental design saves time and money; it also eliminates data misinterpretations caused by erroneous amplifications from retained fragments (see discussion above, under Choose an effective lncRNA target length).

Figure 3. qPCR measures lncRNA knockdown. RNAi reagents or ASOs were transfected into HeLa cells at 2 concentrations—1 or 10 nM—using Lipofectamine® 2000 (ThermoFisher Scientific). The RNA was collected 24 hr after transfection, quantified with 2 triplicate qPCRs (one towards the 5′ end and one towards the 3′ end of each target sequence), and normalized against a control (HPRT expression levels). The data shows that in this case, RNAi reagents were more effective than ASOs at knocking down DANCR, a cytoplasmic lncRNA.

For lncRNAs that are not found in the PrimeTime® Predesigned qPCR Assay Database, we recommend using our PrimerQuest® Tool to design qPCR assays. When using an assay design tool, it is important to perform a BLAST search with the suggested primers and probes to verify specificity. Also select primers that have a lower tendency to form primer-dimers. Contact our application support team for assistance, if necessary.

Understand knockdown duration factors. ASOs that are chemically modified to incorporate a phosphothioroate backbone are extremely stable to degradation by serum and intracellular nucleases. Similarly, RNAi reagents are resistant to intracellular nucleases due to their association with RISC. However, ASOs and siRNAs are diluted with every cell division. Therefore, we can assume the duration of lncRNA knockdown is dependent on the rate of cell division. Whereas knockdown will be long-lasting in non-dividing cells, ASO/siRNA concentration will be diluted with each division in rapidly diving cells, leading to a shorter knockdown duration. More studies are needed, but using HeLa cells—which divide rapidly—we have achieved knockdown of mRNAs for >72 hours with ASOs, and up to 5 days with RNAi.


Use of CRISPR/Cas9 system to knockdown lncRNA

Whereas the CRISPR/Cas9 system will fully disrupt the open-reading of protein-coding genes, its use for lncRNA knockdown requires additional considerations. lncRNAs do not have an open reading frame and may retain function even in the event of a small deletion or insertion. Introducing large genome deletions via CRISPR/Cas9 is feasible, and has been done using a dual guide RNA strategy [7]. Additionally, the CRISPR/Cas9 system can introduce RNA destabilizing elements into a lncRNA, such as poly(A) signals, miRNA binding sites, RNase P substrates, or self-cleaving ribozymes [8].

Kim Lennox has been a research scientist at IDT for 13 years. Her most recent work has shown that effective lncRNA knockdown with antisense and RNAi reagents depends on the localization of the lncRNA in the cell. Her research has also demonstrated how to achieve successful lncRNA knockdown by combining RNAi and ASO reagents.

References

  1. Liu G, Mattick JS, et al. (2013) A meta-analysis of the genomic and transcriptomic composition of complex life. Cell Cycle. 12(13): 2061–2072.
  2. Lennox KA, Owczarzy R, et al. (2013) Improved performance of anti-miRNA oligonucleotides using a novel non-nucleotide modifier. Mol Ther Nucleic Acids. 2: e117.
  3. Lennox KA, Behlke MA. (2011) Chemical modification and design of anti-miRNA oligonucleotides. Gene Ther. 18(12): 1111–1120.
  4. Lennox KA, Sabel JL, et al. Characterization of modified antisense oligonucleotides in Xenopus laevis embryos. Oligonucleotides. 16(1): 26–42.
  5. Fritah S, Niclou S, Azuaje F. (2014) Databases for lncRNAs: a comparative evaluation of emerging tools. RNA. 20(11): 1655–1665.
  6. Gupta N, Fisker N, et al. (2010) A Locked Nucleic Acid antisense oligonucleotide (LNA) silences PCSK9 and snhances LDLR expression in vitro and in vivo. PLoS One. 5(5): e10682.
  7. Ho TT, Zhou N, et al. (2014) Targeting non-coding RNAs with the CRISPR/Cas9 system in human cell lines. Nucleic Acids Res. 43(3): e17.
  8. Gutschner T, Baas M, Diederichs S. (2011) Noncoding RNA gene silencing through genomic integration of RNA destabilizing elements using zinc finger nucleases. Genome Res. 21(11): 1944–1954.

 

Product focus

  • The Unafold tool is free, online, secondary structure prediction software. The program calculates the probability of single-stranded RNA or DNA folding, or hybridization between 2 single strands. Access the UNAFold tool here.
  • ASOs (antisense oligonucleotides) are short, synthetic 15–25 nt oligonucleotides that lo¬calize to the nucleus. They are ordered as desalted DNA oligos, and include phospho¬rothioate (PS) linkages that confer nuclease resistance, thus enhancing intracellular stability. 2′-O-methyl RNA bases can be added in addition to the PS linkages to decrease toxicity and increase ASO efficacy. You can learn more about ASOs and order them from the Antisense Oligonucleotides product page of the IDT website.
  • DsiRNA (Dicer-substrate RNAs) are chemically synthesized 27mer duplex RNAs that have increased potency in RNAi experiments compared to traditional siRNAs. Learn more about DsiRNAs and order them from the DsiRNA product page of the IDT website.

Additional reading

Author: Nolan Speicher is a scientific writing intern at IDT, and Kim Lennox is a research scientist at IDT.

© 2015 Integrated DNA Technologies. All rights reserved. Trademarks contained herein are the property of Integrated DNA Technologies, Inc. or their respective owners. For specific trademark and licensing information, see www.idtdna.com/trademarks.


siRNAs with increased potency

Use IDT DsiRNAs to engage the Dicer-processing/RISC-loading mechanisms and get increased silencing potency over traditional siRNAs.

Learn more ≫


Related Articles

RNAi and DsiRNA: Pathway, Mechanism, and Design

An overview of the RNA interference (RNAi) pathway, its applications, and design considerations for gene silencing experiments.

Read more ≫

Using Antisense Technologies to Modulate Noncoding RNA Function

Useful modifications and design considerations for effective antisense oligonucleotides.

Read more ≫

Small RNA Therapies for Cystic Fibrosis

DsiRNAs are used to develop a protocol for efficient small RNA delivery into airway epithelia to study of miRNA regulation of airway fluid and electrolyte transport.

Read more ≫

Using DsiRNA to Map Pain Pathways in the CNS

Canadian laboratory targets pain receptors for expression knock out via in vivo delivery of DsiRNA 27mer duplex RNAs into the mouse CNS.

Read more ≫

The Future of RNAi and Aptamer Technologies—An Interview with John Rossi

An interview with Dr John Rossi, whose research focuses on the biology and applications of eukaryotic small RNAs and, in particular, their therapeutic use in HIV/AIDS and cancer.

Read more ≫